Schrör K
Institut für Pharmakologie und klinische Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany.
Z Kardiol. 2004;93 Suppl 1:I1-3. doi: 10.1007/s00392-004-1101-1.
The pharmacological evaluation of medications used in secondary prevention of myocardial infarction offers interesting insights that facilitate the individualization of therapy. One example is the strong evidence of a reduced patient benefit with comedication of ACE inhibitors and acetylsalicylic acid after myocardial infarction. Over the past years, the effects of n-3-polyunsaturated-fatty acids after myocardial infarction have been investigated intensely. They act via several physiological mechanisms that are of potential benefit in reducing cardiovascular mortality. While epidemiological and study data suggest antiarrhythmic properties as the main reason for reduced mortality, recent papers also point to a intensification of plaque stability.
对用于心肌梗死二级预防的药物进行药理学评估可提供有趣的见解，有助于实现治疗个体化。一个例子是有强有力的证据表明，心肌梗死后联合使用血管紧张素转换酶抑制剂和乙酰水杨酸会降低患者获益。在过去几年中，人们对心肌梗死后n-3多不饱和脂肪酸的作用进行了深入研究。它们通过几种生理机制发挥作用，这些机制在降低心血管死亡率方面具有潜在益处。虽然流行病学和研究数据表明抗心律失常特性是死亡率降低的主要原因，但最近的论文也指出其可增强斑块稳定性。
